Monte Rosa Therapeutics' Interim Data From an Ongoing Phase 1 Trial of MRT-8102 Shows C-Reactive Protein Level Reductions in Cardiovascular and Cardiometabolic Diseases
Benzinga Newsdesk 10 months ago
BiotechHealth CareGeneral
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and
- In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation
- After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk
- Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts demonstrated deep and sustained NEK7 degradation at doses from 5 mg to 400 mg
- Favorable safety profile observed with mild to moderate adverse events (AEs) and no evidence of increased infection risk
- Ongoing GFORCE-1 Study of MRT-8102 in subjects with elevated CVD risk expanded to multiple dose levels to accelerate development in atherosclerotic cardiovascular disease (ASCVD); anticipated readout in H2 2026
- Plan to initiate Phase 2 ASCVD study in 2026; additional indications being evaluated